We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments
News

Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments

Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments
News

Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncos Therapeutics Raises €4 Million from Healthcap to Develop Oncolytic Viruses into Cancer Treatments"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncos Therapeutics, a biotech company developing new cancer therapeutics based on its next generation oncolytic viruses, completed a € 4 million ($ 5.5 million) investment from HealthCap. With committed capital exceeding € 800 million, HealthCap is one of the largest specialized providers of venture capital within life sciences in Europe.

After treating 200 late stage cancer patients since 2007 with strong safety and efficacy results, Oncos has selected its modified oncolytic adenovirus CGTG-102 as its lead clinical candidate. “This is the first step to turn our Advanced Therapy Access Program results into cancer therapeutics”, comments Pekka Simula, CEO and co-founder.

“The results have been strong for late stage solid tumor cancers where routine therapies have failed. Time is critical in the treatment of cancer. We are confident that when treating earlier stage patients, our oncolytic virus therapy will prove even more significant”, continues Research Professor Akseli Hemminki, CSO and co-founder.

“Oncolytic viruses are maturing as a new treatment modality in cancer. Oncos, as one of the leading companies in the field, and combines very promising results in humans with strong science”, comments Dr Johan Christensen, partner at HealthCap.
Advertisement